Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 400 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 400 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $30.00, for a total transaction of $12,000.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares in the company, valued at $336,690. This represents a 3.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $15,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Stock Down 0.3%

Shares of Capricor Therapeutics stock traded down $0.09 during trading on Wednesday, reaching $29.51. 803,008 shares of the company were exchanged, compared to its average volume of 955,468. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The business has a 50-day moving average price of $30.26 and a 200-day moving average price of $28.40. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -12.72 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities research analysts forecast that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth $43,516,000. Darwin Global Management Ltd. bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth $23,168,000. Finally, SB Capital Management Inc acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $11,544,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CAPR shares. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Roth Mkm reiterated a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a report on Friday, May 15th. B. Riley Financial lifted their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Piper Sandler restated an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $48.36.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.